GlassScriptPhysician profile
Melanie R Senn
NPI 1649604505
$8,825.97
in general payments reported to CMS, 2019-2025
29 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2022: $2,184 · 2023: $2,032 · 2024: $2,639 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,767 · Education: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,766.76 |
| Education | $550.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,156.89 | 2021-2025 | |
| Janssen Biotech, INC. | $1,273.99 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $853.74 | 2022-2025 | Sotyktu |
| Amgen INC. | $698.27 | 2021-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $674.79 | 2022-2025 | Ilumya, Winlevi, Blu-U |
| Novartis Pharmaceuticals Corporation | $588.07 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $436.58 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $434.20 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $368.05 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $270.57 | 2022-2025 | |
| Leo Pharma INC. | $186.68 | 2022-2024 | Adbry |
| Janssen Scientific Affairs, LLC | $149.10 | 2022 | |
| Pfizer INC. | $144.10 | 2022-2025 | |
| Organon LLC | $84.43 | 2024 | |
| Dermavant Sciences, INC. | $65.06 | 2022-2023 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $61.30 | 2022 | |
| Genentech USA, INC. | $52.82 | 2021-2022 | |
| Galderma Laboratories, L.P. | $49.41 | 2024-2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $37.54 | 2022-2023 | Valchlor |
| Organogenesis INC. | $33.15 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.86 | 2024 | Spevigo |
| Biowound Solutions, INC. | $29.86 | 2025 | Bio-Connekt |
| Paratek Pharmaceuticals, INC. | $29.41 | 2023 | Nuzyra |
| Sandoz INC. | $29.12 | 2023-2024 | Hyrimoz |
| Krystal Biotech INC | $23.87 | 2025 | Vyjuvek |
| Biocon Biologics INC | $18.67 | 2023 | Hulio |
| Integra Lifesciences Corporation | $15.99 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Arcutis Biotherapeutics, INC. | $14.81 | 2025 | Zoryve |
| Kerecis Limited | $13.64 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Senn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.